Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial.

By T. Takayama, T. Sekine, M. Makuuchi, S. Yamasaki, T. Kosuge, J. Yamamoto, K. Shimada, M. Sakamoto, S. Hirohashi, Y. Ohashi and 1 more. The Lancet, 2000

878 citations recorded by the source corpus.

Subfields: Hepatology, Oncology

View Paper: https://www.semanticscholar.org/paper/1786c9f489c012ff2d73230d654cbb6e98a42294

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hepatology

1. Jordi Bruix1 , 2
2. J. Llovet
3. M. Sherman
4. Riccardo Lencioni
5. V. Mazzaferro
6. Andrew X. Zhu
7. Peter R. Galle
8. T. de Baère

In Oncology

1. Jordi Bruix1 , 2
2. V. Mazzaferro
3. J. Llovet
4. I. Melero

Citations in the corpus

• EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. (2012, background): “Adoptive immunotherapy with activated lymphocytes with interleukin-2 reduced first recurrence in a trial with 150 patients (3-year recurrence: 33% versus 48% in the control group) [205].”
• Novel advancements in the management of hepatocellular carcinoma in 2008. (2008, background): “Adoptive immunotherapy by activated lymphocytes with interleukin-2 and antibody to CD3 reduced first recurrence in a trial with 150 patients [67] (3-yr recurrence: 33% vs.”
• A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. (2013, background): “5 [5-7] Child-Pugh stage A 12 (57.”
• Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. (2005, background): “also been shown to increase tumor-free survival after removal of the tumor (6) and first clinical trials using dendritic cells have been initiated (7, 8).”
• Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma (2008, neutral): “Vascular invasion — no. (%) 4 ( 5 ) 74 (34) <0.001”
• Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. (2001, background): “[94] Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, et al.”
• EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. (2012, background): “Adoptive immunotherapy with activated lymphocytes with interleukin-2 reduced first recurrence in a trial with 150 patients (3-year recurrence: 33% versus 48% in the control group) [205].”